Septerna, Inc. (NASDAQ:SEPN) Stock Has Average Price Target of $53.67 According to Analysts

Shares of Septerna, Inc. (NASDAQ:SEPN) have received a consensus rating of “Moderate Buy” from the eleven analysts that are presently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating, eight have assigned a buy rating and one has issued a strong buy rating on the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $53.67.

A number of brokerages have weighed in on SEPN. HC Wainwright increased their target price on shares of Septerna from $40.00 to $60.00 and gave the stock a “buy” rating in a report on Wednesday, August 12th. Wells Fargo & Company upped their price target on shares of Septerna from $50.00 to $61.00 and gave the stock an “overweight” rating in a research report on Wednesday. JonesTrading increased their price objective on shares of Septerna from $43.00 to $62.00 and gave the stock a “buy” rating in a report on Thursday, August 13th. Guggenheim boosted their target price on shares of Septerna from $45.00 to $51.00 and gave the company a “buy” rating in a research note on Tuesday, August 11th. Finally, JPMorgan Chase & Co. upped their target price on shares of Septerna from $38.00 to $48.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 19th.

Insider Buying and Selling

In related news, SVP Daniel D. Long sold 3,333 shares of the business’s stock in a transaction that occurred on Tuesday, September 1st. The shares were sold at an average price of $37.83, for a total value of $126,087.39. Following the sale, the senior vice president directly owned 96,412 shares in the company, valued at $3,647,265.96. The trade was a 3.34% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, COO Elizabeth Bhatt sold 25,000 shares of the company’s stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $44.00, for a total value of $1,100,000.00. Following the sale, the chief operating officer directly owned 174,209 shares of the company’s stock, valued at approximately $7,665,196. This represents a 12.55% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 32,333 shares of company stock worth $1,375,727 in the last quarter. Company insiders own 5.80% of the company’s stock.

Institutional Trading of Septerna

Institutional investors have recently made changes to their positions in the stock. Renaissance Technologies LLC acquired a new stake in Septerna during the first quarter valued at $906,000. TRV GP V LLC acquired a new stake in shares of Septerna in the second quarter worth about $208,160,143. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new stake in shares of Septerna during the 2nd quarter worth about $445,000. First Light Asset Management LLC boosted its stake in shares of Septerna by 31.4% during the 2nd quarter. First Light Asset Management LLC now owns 963,260 shares of the company’s stock worth $32,260,000 after acquiring an additional 230,400 shares in the last quarter. Finally, TRV GP VI LLC acquired a new position in shares of Septerna during the 2nd quarter valued at about $141,048,460.

Septerna Stock Performance

Septerna stock opened at $47.88 on Thursday. The firm has a market capitalization of $2.24 billion, a PE ratio of -88.67 and a beta of 2.20. Septerna has a one year low of $17.55 and a one year high of $51.10. The stock’s 50 day moving average price is $39.21 and its 200 day moving average price is $32.38.

Septerna (NASDAQ:SEPN) last announced its earnings results on Monday, August 10th. The company reported ($0.29) earnings per share for the quarter, beating the consensus estimate of ($0.43) by $0.14. Septerna had a negative return on equity of 9.57% and a negative net margin of 24.51%. The company had revenue of $26.75 million during the quarter, compared to the consensus estimate of $19.22 million. On average, analysts forecast that Septerna will post -1.41 earnings per share for the current fiscal year.

About Septerna

Septerna, Inc is a clinical-stage biotechnology company focused on discovering and developing oral small-molecule medicines that target G protein-coupled receptors (GPCRs). GPCRs are a large class of cell-surface proteins involved in a wide range of biological processes and represent an important source of potential drug targets.

The company’s research is powered by its Native State platform, which is designed to study GPCRs in their natural biological configuration and support the discovery of selective small-molecule compounds.